Evidence map›Paper›PMID 24144687›Full record

Trial reportThe Journal of urology2014

Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

David M Schuster, Peter T Nieh, Ashesh B Jani, Rianot Amzat, F Dubois Bowman, Raghuveer K Halkar, Viraj A Master, Jonathon A Nye, Oluwaseun A Odewole, Adeboye O Osunkoya and 3 more

4 registry-linked trialsAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 76 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00562315 phase2completednot on this map

18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01).

TypeinterventionalSponsorDavid M. Schuster, MDRan2007 to 2015Enrolled128ConditionsProstate CancerArmsFACBC, ProstaScinct
NCT02830880 phase2completednot on this mapstarted 2016, after this paper: background citation

Investigation of Therapy Response With Amino Acid Analogue Transport PET Imaging

TypeinterventionalSponsorEmory UniversityRan2016 to 2019Enrolled7ConditionsProstate CancerArmsFACBC PET-CT, MRI, CT, or Bone Scan
NCT04234399 terminatednot on this mapstarted 2020, after this paper: background citation

Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) PET/CT Utilizing the High Resolution Digital Philips Vereos Scanner, in Patients With Biochemical Recurrence After Radical Prostatectomy

TypeobservationalSponsorUniversity of VermontRan2020 to 2024Enrolled22ConditionsProstatic NeoplasmArmsFluciclovine PET/CT using a digital PET/CT
NCT05936658 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

TypeinterventionalSponsorFutureChemRan2023 to 2025Enrolled138ConditionsHigh Risk Prostate CarcinomaArms[F-18]Florastamin
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 1 synthesis or guideline pooled it, 171 citations in OpenAlex.

  1. [European journal of nuclear medicine and molecular imaging · 2020
    Guideline
  2. AnCurrent radiopharmaceuticals · 2024
    Trial
  3. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Trial
  4. Diagnostic Performance ofClinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  5. Lancet (London, England) · 2021
    Trial
  6. [The Journal of urology · 2020
    Trial
  7. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  8. Trial
  9. A PET/MRI study towards finding the optimal [European journal of nuclear medicine and molecular imaging · 2017
    Trial
  10. Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017
    Trial
  11. Trial
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. [Cancers · 2022
    Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

David M SchusterDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia. Electronic address: dschust@emory.edu.
Peter T NiehDepartment of Urology, Emory University, Atlanta, Georgia.
Ashesh B JaniDepartment of Radiation Oncology, Emory University, Atlanta, Georgia.
Rianot AmzatDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
F Dubois BowmanDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia.
Raghuveer K HalkarDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Viraj A MasterDepartment of Urology, Emory University, Atlanta, Georgia.
Jonathon A NyeDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Oluwaseun A OdewoleDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Adeboye O OsunkoyaDepartment of Urology, Emory University, Atlanta, Georgia; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.
Bital Savir-BaruchDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Pooneh Alaei-TaleghaniDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Mark M GoodmanDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Emory University · US

Funding

MOLECULAR IMAGING DIRECTED, 3D ULTRASOUND-GUIDED, BIOPSY SYSTEMR01CA156775 · NCI · UNIVERSITY OF TEXAS DALLAS · PI FEI, BAOWEI · 2011 to 2016
$1.7M
18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate CarcinomaR01CA129356 · NCI · EMORY UNIVERSITY · PI SCHUSTER, DAVID MICHAEL · 2007 to 2011
$1.6M
Targeted fusion biopsy using anti-[18F]FACBC PET/CT and real-time 3D ultrasound gR21CA176684 · NCI · EMORY UNIVERSITY · PI FEI, BAOWEI, MASTER, VIRAJ · 2013 to 2014
$568k
NCI NIH HHS 5R01CA129356NCI NIH HHS R01 CA129356NCI NIH HHS R01 CA156775NCI NIH HHS R21 CA176684
6 · The paper itself

Abstract

purposeWe prospectively evaluated the amino acid analogue positron emission tomography radiotracer anti-3-[(18)F]FACBC compared to ProstaScint® ((111)In-capromab pendetide) single photon emission computerized tomography-computerized tomography to detect recurrent prostate carcinoma. MATERIALS AND

methodsA total of 93 patients met study inclusion criteria who underwent anti-3-[(18)F]FACBC positron emission tomography-computerized tomography plus (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for suspected recurrent prostate carcinoma within 90 days. Reference standards were applied by a multidisciplinary board. We calculated diagnostic performance for detecting disease.

resultsIn the 91 of 93 patients with sufficient data for a consensus on the presence or absence of prostate/bed disease anti-3-[(18)F]FACBC had 90.2% sensitivity, 40.0% specificity, 73.6% accuracy, 75.3% positive predictive value and 66.7% negative predictive value compared to (111)In-capromab pendetide with 67.2%, 56.7%, 63.7%, 75.9% and 45.9%, respectively. In the 70 of 93 patients with a consensus on the presence or absence of extraprostatic disease anti-3-[(18)F]FACBC had 55.0% sensitivity, 96.7% specificity, 72.9% accuracy, 95.7% positive predictive value and 61.7% negative predictive value compared to (111)In-capromab pendetide with 10.0%, 86.7%, 42.9%, 50.0% and 41.9%, respectively. Of 77 index lesions used to prove positivity histological proof was obtained in 74 (96.1%). Anti-3-[(18)F]FACBC identified 14 more positive prostate bed recurrences (55 vs 41) and 18 more patients with extraprostatic involvement (22 vs 4). Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography correctly up-staged 18 of 70 cases (25.7%) in which there was a consensus on the presence or absence of extraprostatic involvement.

conclusionsBetter diagnostic performance was noted for anti-3-[(18)F]FACBC positron emission tomography-computerized tomography than for (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for prostate carcinoma recurrence. The former method detected significantly more prostatic and extraprostatic disease.

Indexed as

Antibodies, MonoclonalCarboxylic AcidsCyclobutanesIndium RadioisotopesMultimodal ImagingPositron-Emission TomographyTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedAgedAged, 80 and overCarcinomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesAntibodies, MonoclonalCapromab PendetideCarboxylic AcidsCyclobutanesfluciclovine F-18Indium Radioisotopes1-amino-3-fluorocyclobutane-1-carboxylic acidcapromab pendetideemission-computedphotonpositron-emission tomographyprostatic neoplasmstomography

Identifiers

PMID24144687
PMCPMC4155751
OpenAlexW2150566177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.